Tymlos/Abaloparatide Cost, Side effects, Dosage, Uses for postmenopausal osteoporosis

Tymlos/Abaloparatide Cost, Side effects, Dosage, Uses for postmenopausal osteoporosis. US FDA granted approval of Tymlos to Radius Health, Inc.

US FDA approved new medicine Tymlos that contains active pharmaceutical ingredient abaloparatide for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Tymlos/Abaloparatide is parathyroid hormone related protein (PTHrP) and is anabolic agent used to increase bone densification.

Tymlos/Abaloparatide is analogus drug that binds with parathyroid hormone 1 receptor  (PTH1R) which results in activation of Cyclic adenosine monophosphate (cAMP). Cyclic adenosine monophosphate is important compound for intracellular signal transduction in many biological process. This cAMP increase bone densification and mineralization (BMD and BMC) resulting in increase bone strength .

Osteoporosis is worldwide common disease that increase the risk of fractures and bone deformity due to bone demineralization and fragility.  Most commonly affected bones are back bones, forearm bones, hip bone etc. Persistent pain may hinder to carry out routine activities. Osteoporosis symptoms are not obvious initially but later on excessive demineralization may lead to fractures.

Being old, is a major risk factor for osteoporosis. This risk may increase two times in women due to hormonal imbalance after age 40's of 50's. Certain diseases like diabetes, adrenal insufficiency, crohn's disease, coeliac disease, malabsorption disturb calcium phosphorus balance in the body that may lead to osteoporosis if persist for a long term.

Tymlos/Abaloparatide Side effects

According to data provided by health authorities this drug exhibit following side effects during clinical trials

• Hypercalciuria
• Dizziness
• Nausea
• Headache 
• Palpitations
• Fatigue
• Upper abdominal pain
• Vertigo

US FDA also instruct for box warning that tymlos/abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats; this effect was observed at systemic exposures to abaloparatide ranging from  4-28 times the exposure in humans receiving the 80-mcg dose.

Tymlos/Abaloparatide Uses/Prescribing Information

US FDA approved new medicine Tymlos that contains active pharmaceutical ingredient abaloparatide for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Tymlos/Abaloparatide is parathyroid hormone related protein (PTHrP) and is anabolic agent used to increase bone densification.

Tymlos/Abaloparatide Dosage

This drug is formulated as 80mcg/40mcL (available as a pre-filled pen that delivers 30 daily doses of 80mcg). However, standard dosage frequency is 80mcg subcutaneously once a day. Dose tit-ration should be considered in patient having liver or kidney impairment.